Welcome!

News Feed Item

Caris Molecular Intelligence™ Identifies Key Biomarkers of Clinical Benefit and Resistance to Chemotherapy through Multi-Technology Tumor Profiling

Peer-Reviewed Case Study from Fox Chase Cancer Center Demonstrates Value of Company's Unique Approach to Precision Medicine to Uncover Critical Treatment Insights

IRVING, Texas, Aug. 5, 2014 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of precision medicine, announced today publication of a case study in which the company's comprehensive tumor profiling service, Caris Molecular Intelligence™, helped guide successful anticancer treatment for a patient with neuroendocrine carcinoma. The case study, published in the Journal of the National Comprehensive Cancer Network (JNCCN) by researchers from Fox Chase Cancer Center, offers guidance to oncologists seeking to personalize treatment to individual patients' tumors by way of multi-technology tumor profiling.

"The data outlined in this peer-reviewed case study clearly shows that Caris Molecular Intelligence's multi-technology approach to tumor profiling is an essential tool for individualization of cancer treatment," said David D. Halbert, Chairman and CEO of Caris Life Sciences. "In this case report, DNA sequencing and immunohistochemistry analysis were integral to uncovering life-changing drug options for the patient. This powerful example further validates our approach, which we know provides the most actionable treatment information for doctors and their patients." 

Successful Imatinib Therapy for Neuroendocrine Carcinoma with Activating KIT Mutation

The JNCCN paper represents the first documented case of an activating KIT mutation in a neuroendocrine tumor (NET) and of successful treatment with both a kinesin 11 (KIF11) inhibitor and imatinib. The patient, a 48-year-old man with a refractory, metastatic NET who was unresponsive to conventional chemotherapy, was treated with a KIF11 inhibitor in a phase I clinical trial, with a clinically meaningful partial response. However, after 20 months, the patient experienced tumor progression.

Immunohistochemistry (IHC) analysis through Caris Molecular Intelligence revealed an activating mutation in exon 11 of the KIT receptor tyrosine kinase, which has been associated with response to imatinib in patients with gastrointestinal stromal tumors (GIST). After two weeks of imatinib therapy, the patient's pain improved and the presence of disease significantly declined. After two months of treatment, the patient's recurrent hepatomegaly (abnormally enlarged liver) had normalized, and a liver CT scan confirmed a marked reduction of hepatic lesions. At the time this case report was written, 46 months after his initial diagnosis, the patient had been treated with imatinib for 12 months with good tolerability and no signs of cancer in radiographic imaging.

"In this case, use of multi-platform molecular profiling confirmed the potential benefit of imatinib, which led to impressive symptomatic and radiographic improvements for the patient," noted study co-investigator Igor Astsaturov, MD, PhD, Medical Oncologist at Fox Chase Cancer Center in Philadelphia, PA. "These data further support the approach of molecular characterization of individual tumors as a means to improve anticancer treatment. Such efforts may serve not only to identify new therapeutic targets, but also to tease out the subset of patients who truly derive benefit from largely discarded therapeutic approaches."

About Caris Molecular Intelligence

Caris Molecular Intelligence™, the industry's leading cancer molecular profiling service, helps oncologists treat cancer smarter by delivering the most potential treatment options for patients. This service has been used by more than 6,500 oncologists to develop individualized and actionable treatment plans for more than 65,000 cancer patients in 59 countries across the globe. Caris Molecular Intelligence integrates the latest relevant panomics data -- the combination of genes, proteins, molecular pathways, and unique patient characteristics -- from clinical studies in cancer and cancer biology to identify the most clinically actionable drug associations approved by the U.S. Food & Drug Administration (FDA) or in active clinical trials in the United States. Beyond standard DNA analysis, Caris Molecular Intelligence assesses all relevant biological components, such as RNA, protein expression and gene amplification levels, to provide oncologists with the most treatment options for their patients. Currently, Caris can identify therapeutic guidance for up to 51 FDA-approved drug associations, far exceeding the 19 that can be identified using next-generation sequencing alone. This therapeutic guidance is electronically delivered to the ordering physician in an easy-to-read report that enables development of tailored treatment plans. For more information on Caris Molecular Intelligence, visit www.carismolecularintelligence.com. The Caris Registry™ is a database of clinicopathologic and outcome variables from consenting patients whose tumors underwent multi-technology profiling by Caris Molecular Intelligence™.

About Caris Life Sciences

Caris Life Sciences is a leading biosciences company focused on fulfilling the promise of precision medicine. Caris Molecular Intelligence™, the industry's first and largest tumor profiling service, provides an oncologist with the most potentially clinically actionable treatment options available to personalize care today. Using a variety of advanced and clinically-relevant technologies that assess all relevant biological components of a patient's cancer, Caris Molecular Intelligence correlates molecular data generated from a tumor with biomarker/drug associations derived from clinical cancer literature. The company is also developing a series of blood tests based on its proprietary Carisome® TOP™ platform, a revolutionary blood-based testing technology for diagnosis, prognosis, and theranosis of cancer and other complex diseases. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe, Australia and other international markets. To learn more, please visit www.carislifesciences.com.

SOURCE Caris Life Sciences

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Isomorphic Software will exhibit at DevOps Summit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Isomorphic Software provides the SmartClient HTML5/AJAX platform, the most advanced technology for building rich, cutting-edge enterprise web applications for desktop and mobile. SmartClient combines the productivity and performance of traditional desktop software with the simp...
With so much going on in this space you could be forgiven for thinking you were always working with yesterday’s technologies. So much change, so quickly. What do you do if you have to build a solution from the ground up that is expected to live in the field for at least 5-10 years? This is the challenge we faced when we looked to refresh our existing 10-year-old custom hardware stack to measure the fullness of trash cans and compactors.
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
The emerging Internet of Everything creates tremendous new opportunities for customer engagement and business model innovation. However, enterprises must overcome a number of critical challenges to bring these new solutions to market. In his session at @ThingsExpo, Michael Martin, CTO/CIO at nfrastructure, outlined these key challenges and recommended approaches for overcoming them to achieve speed and agility in the design, development and implementation of Internet of Everything solutions wi...
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
With over 720 million Internet users and 40–50% CAGR, the Chinese Cloud Computing market has been booming. When talking about cloud computing, what are the Chinese users of cloud thinking about? What is the most powerful force that can push them to make the buying decision? How to tap into them? In his session at 18th Cloud Expo, Yu Hao, CEO and co-founder of SpeedyCloud, answered these questions and discussed the results of SpeedyCloud’s survey.
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
Actian Corporation has announced the latest version of the Actian Vector in Hadoop (VectorH) database, generally available at the end of July. VectorH is based on the same query engine that powers Actian Vector, which recently doubled the TPC-H benchmark record for non-clustered systems at the 3000GB scale factor (see tpc.org/3323). The ability to easily ingest information from different data sources and rapidly develop queries to make better business decisions is becoming increasingly importan...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...
Qosmos has announced new milestones in the detection of encrypted traffic and in protocol signature coverage. Qosmos latest software can accurately classify traffic encrypted with SSL/TLS (e.g., Google, Facebook, WhatsApp), P2P traffic (e.g., BitTorrent, MuTorrent, Vuze), and Skype, while preserving the privacy of communication content. These new classification techniques mean that traffic optimization, policy enforcement, and user experience are largely unaffected by encryption. In respect wit...
Deploying applications in hybrid cloud environments is hard work. Your team spends most of the time maintaining your infrastructure, configuring dev/test and production environments, and deploying applications across environments – which can be both time consuming and error prone. But what if you could automate provisioning and deployment to deliver error free environments faster? What could you do with your free time?
SYS-CON Events announced today that Hitrons Solutions will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Hitrons Solutions Inc. is distributor in the North American market for unique products and services of small and medium-size businesses, including cloud services and solutions, SEO marketing platforms, and mobile applications.
Smart Cities are here to stay, but for their promise to be delivered, the data they produce must not be put in new siloes. In his session at @ThingsExpo, Mathias Herberts, Co-founder and CTO of Cityzen Data, will deep dive into best practices that will ensure a successful smart city journey.
SYS-CON Events announced today that 910Telecom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Housed in the classic Denver Gas & Electric Building, 910 15th St., 910Telecom is a carrier-neutral telecom hotel located in the heart of Denver. Adjacent to CenturyLink, AT&T, and Denver Main, 910Telecom offers connectivity to all major carriers, Internet service providers, Internet backbones and ...
SYS-CON Events announced today that eCube Systems, a leading provider of middleware modernization, integration, and management solutions, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. eCube Systems offers a family of middleware evolution products and services that maximize return on technology investment by leveraging existing technical equity to meet evolving business needs. ...